Vilaprisan

Uterine fibroids (UF) are common gynecological affections in women of reproductive age. These tumors can be asymptomatic in the majority of cases; nonetheless, they can be responsible for a multitude of clinical presentations such as abnormal uterine bleeding, chronic pelvic pain, infertility and other obstetric complications, which may significantly impact the quality of life of patients affected. At the moment, hormonal pharmacological strategies are used in the clinical practice aiming to control women’s symptoms and improve hemoglobin level before surgery. Among these, selective progesterone receptor modulators (SPRMs) have been investigated. After the wide clinical use of ulipristal acetate, vilaprisan, a novel SPRM, is currently being deeply investigated in late phase II-III trials for the treatment of UF. The aim of this brief monograph is to review the literature on the pharmacodynamics, pharmacokinetics, clinical efficacy and safety of vilaprisan for treating UF.